期刊文献+

Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma

暂未订购
导出
摘要 Objective:The aim of the current study was to identify independent prognostic factors,evaluate differential adjuvant chemotherapy efficacy across clinicopathologic subgroups,and define adjuvant chemotherapy-sensitive populations.Methods:A retrospective analysis of 168 AAC patients undergoing curative pancreaticoduodenectomy(2011-2020)was performed.Cases were classified into intestinal(28.0%),pancreatobiliary(30.4%),and mixed subtypes(18.5%)per NCCN(v2.2025)criteria.Independent prognostic factors for AAC patients were identified through uni-and multi-variable Cox proportional hazards modeling and subgroup analyses were stratified by age range,gender,differentiation,T stage,N stage,BVI,TDs,and PNI.Results:The pancreatobiliary signature(HR=2.884,P<0.001)and BVI(HR=2.330,P=0.001)were independent poor prognostic factors.Adjuvant chemotherapy improved overall survival(OS)in the following AAC patients:T3-T4 stage(HR=0.485,P=0.050);N1-N2 stage(HR=0.365,P=0.008);and TD-positive(HR=0.401,P=0.026).The median OS increased from 22.3-51.3 months with adjuvant chemotherapy in TD-positive patients(P=0.019).TD positivity conferred a worse prognosis in BVI-negative subgroups(OS:HR=3.840,95%CI:2.058-7.166,P<0.001;and progression-free survival(PFS):HR=2.950,95%CI:1.550-5.617,P=0.002).Conclusions:The pancreatobiliary signature and BVI constitute critical high-risk pathologic features in AAC.TD status identified high-risk cohorts,thus enabling postoperative risk-stratified treatment strategies.In patients negative for pancreatobiliary signature or BVI,TD positivity predicted significantly worse survival.
机构地区 Pancreas Center
出处 《Cancer Biology & Medicine》 2025年第10期1255-1266,I0037-I0041,共17页 癌症生物学与医学(英文版)
基金 supported by the National Key Research and Development Program of China(Grant No.2021YFA1201100) the Projects of Tianjin Science and Technology Bureau National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine(Grant Nos.24ZXZSSS00440 and 22ZXJBSY00030) the Science&Technology Development Fund of Tianjin Education Commission for Higher Education(Grant No.2022ZD067) the Tianjin Key Medical Discipline(Specialty)Construction Project(Grant No.TJYXZDXK-009A).
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部